Gotenfia is a biosimilar medicine with the active ingredient golimumab, which is a human monoclonal antibody that inhibits TNF-α.1 It blocks TNF-α, thereby reducing inflammation and other symptoms of the diseases for which it is used.1 Gotenfia is highly similar to the reference medicine Simponi, authorised in the EU1. It is available as a 50 mg and 100 mg solution for injection in prefilled syringes.1 In combination with MTX, it is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children aged 2 years and older with an inadequate response to previous MTX therapy.[1] Alone or with MTX, it treats active and progressive psoriatic arthritis in adults with inadequate response to prior DMARD therapy and slows the progression of peripheral joint damage.[1] It is also indicated for the treatment of adults with severe active non-radiographic axial spondylarthritis with objective signs of inflammation (elevated CRP or MRI evidence) who have not responded to or are intolerant of NSAIDs.EPAR status is an opinion[1].